By Donald Zuhn --
Ryogen LLC announced today that it had been granted U.S. Patent No. 7,273,718. The '718 patent, which relates to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, appears to be the Suffern, New York-based genomics company's second U.S. patent. According to Ryogen's website, the company, which is a portfolio company of IP Holdings LLC, was formed for the purpose of licensing U.S. Patent No. 6,399,349, which is directed to the human aminopeptidase P gene.
The '718 patent issued from U.S. Application No. 10/457,715, filed June 9, 2003, and claims the benefit of U.S. Provisional Application No. 60/386,941, filed June 7, 2002. Representative independent claims 1 and 8 of the '718 patent recite:
1. An isolated genomic polynucleotide, wherein said polynucleotide can be isolated from human chromosome 10 and is selected from the group consisting of:
(a) a polynucleotide consisting of the nucleic acid sequence set forth in SEQ ID NO:2,
(b) a polynucleotide consisting of the sequence of nucleotides from position 12803 to position 55760 of SEQ ID NO:2, and
(c) a polynucleotide which is the complement of a polynucleotide of (a) or (b) and encodes a polypeptide having aminoacyl prolyl peptidyl hydrolase activity.8. An isolated polynucleotide consisting of a nucleic acid sequence selected from the group consisting of
(a) a sequence of at least 5000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 1 through position 12802 of SEQ ID NO:2,
(b) a sequence of at least 2000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 55761 through position 58735 of SEQ ID NO:2,
(c) a sequence of nucleotides complementary to the nucleotide sequence of (a), and
(d) a sequence of nucleotides complementary to the nucleotide sequence of (b).
Comments